Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin vs Hydrochlorothiazide in Recurring Kidney Stones
NCT05443932Phase 4Not yet recruiting
- Sponsor
- Medical University of Vienna
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in urolithiasis, hyperoxaluria, sponsored by Medical University of Vienna. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
urolithiasishyperoxaluria
Beyond the preview
Go deeper on NCT05443932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05443932.